샘플 요청 목록

 카트 문의
시장보고서
상품코드
1744904

세계의 경동맥 화학색전술(TACE) 시장

Transarterial Chemoembolization
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 375 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 경동맥 화학색전술(TACE) 시장은 2030년까지 218억 달러에 이를 전망

2024년에 168억 달러로 추정되는 경동맥 화학색전술(TACE) 세계 시장은 2024-2030년 분석 기간에 CAGR 4.5%로 성장하여 2030년에는 218억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 화학요법제는 CAGR 4.3%를 나타내고, 분석 기간 종료시에는 115억 달러에 이를 것으로 예측됩니다. 방사선 치료제 부문의 성장률은 분석 기간중 CAGR 5.1%로 추정됩니다.

미국 시장은 추정 46억 달러, 중국은 CAGR 8.1%로 성장 예측

미국의 경동맥 화학색전술(TACE) 시장은 2024년에 46억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 45억 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 8.1%로 추정됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 1.9%와 3.5%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 2.6%를 보일 전망입니다.

세계의 '경동맥 화학색전술(TACE)' 시장 - 주요 동향과 촉진요인 정리

경동맥 화학색전술이 전 세계 간암 치료의 표준이 되고 있는 이유는?

경동맥화학색전술(TACE)은 원발성 간암 중 가장 흔한 형태인 중기 간세포암(HCC)에 대한 치료법으로 선호되고 표준화된 치료법입니다. 전신 화학요법과 달리, TACE는 종양에 영양을 공급하는 간동맥에 고용량의 화학요법을 직접 투여하고 동시에 혈액 공급을 차단하여 약물의 표적 노출과 종양 국소 괴사를 유도합니다. 이러한 이중 메커니즘으로 인해 TACE는 외과적 절제술이나 간 이식이 부적합한 환자에게 특히 효과적임이 입증되었으며, 이식을 기다리는 환자들의 연결 요법으로 채택되어 병의 진행을 안정화시키는 데 도움이 되고 있습니다. 전 세계적으로 만성 B형 및 C형 간염 감염, 비알코올성 지방간질환(NAFLD), 알코올성 간손상 등의 요인으로 인해 간암 발생률이 증가하고 있습니다. 이러한 추세로 인해 전신 독성 프로파일이 낮고 생존율과 질병 조절을 개선하는 TACE와 같은 국소 치료법에 대한 수요가 증가하고 있습니다. 국제 종양학회의 새로운 가이드라인은 TACE를 간암의 최전선 또는 병용요법으로 권장하고 있으며, 이는 치료 경로에서 TACE의 중심적인 역할을 강화하여 전 세계 의료진 사이에서 TACE의 채택을 촉진하고 있습니다.

약물 전달의 혁신과 영상 기술이 TACE의 치료 성적을 어떻게 향상시키고 있는가?

색전 물질, 카테터 기술 및 영상 유도 시스템의 발전으로 TACE의 효능이 크게 향상되었습니다. 약물 용출성 비드(DEB)는 종양 부위에서 화학요법제의 제어 및 서방형 방출을 가능하게 하여 전신 노출을 줄이고 반응률을 향상시키면서 많은 시장에서 기존 리피오돌 기반 제제를 대체하고 있습니다. 마이크로카테터와 조향식 전달 시스템의 기술적 향상으로 복잡한 혈관 해부학적 구조를 정확하게 탐색할 수 있게 되어 건강한 간 조직 손상을 최소화할 수 있게 되었습니다. 동시에, 콘빔 CT나 3D 혈관조영술과 같은 실시간 영상화 기술은 치료 중 시각화에 혁명을 일으켜 고도로 표적화된 전달과 치료의 성공 여부를 즉각적으로 확인할 수 있게 되었습니다. 이러한 혁신은 또한 종양의 크기, 위치, 혈관이 색전증 유형, 입자 크기, 투여 스케줄 결정에 반영되는 개인화된 치료 계획의 길을 열었습니다. 또한, 영상 분석에 AI를 통합하여 중재적 영상의학과 전문의의 치료 전 계획과 치료 후 결과 평가에 도움을 주어 일관성과 장기 예후를 개선하기 시작했습니다. 이러한 기술 주도의 개선은 임상 결과를 개선할 뿐만 아니라 TACE 후보군을 확대하는 데에도 기여하고 있습니다.

전 세계 헬스케어 환경은 TACE의 보급을 위한 준비가 되어 있는가?

세계 헬스케어 생태계는 중재적 방사선 인프라의 확대와 숙련된 전문 증가에 힘입어 경동맥화학색전술의 광범위한 도입에 점점 더 적극적으로 나서고 있습니다. 고소득 국가에서는 정교한 영상진단실, 다학제 종양위원회, 종양학 전용 경로의 존재로 인해 TACE를 간암 치료 알고리즘에 원활하게 통합할 수 있게 되었습니다. 한편, 중진국에서는 첨단 수술이나 전신치료에 대한 접근성이 제한적인 자원이 부족한 환경에서 TACE의 가치를 인식하고 최소침습적 암 치료에 많은 투자를 하고 있습니다. 특히 간암 발병률이 높은 아시아태평양에서는 각국 정부가 TACE를 공공 보험 제도와 국가 암 대책 프로그램에 포함시키면서 시장 확대에 박차를 가하고 있습니다. 외래수술센터(ASC)와 종양 전문 병원에 대한 민간 부문의 투자도 도시 및 도시 근교 지역에서 TACE의 접근성을 높이는 데 기여하고 있습니다. 그러나 저소득 국가에서는 여전히 부족한 영상 진단 기능과 숙련된 중재적 방사선 전문의의 부족이 문제점으로 남아있습니다. 이동형 IR 장치, 교육 프로그램, 민관 파트너십을 통해 접근성을 개선하려는 국제 의료기관의 노력은 이러한 격차를 해소하기 시작했으며, 생명 연장 치료에 대한 접근성을 점차 민주화시키고 있습니다.

경동맥 화학 색전술 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다.

경동맥 화학색전술 시장의 성장은 질병 유행, 의료 기술 혁신, 의료 시스템 발전에 기반한 여러 요인에 의해 주도되고 있습니다. 주요 촉진요인은 고령화, 바이러스성 간염, 알코올 섭취, 대사 장애로 인한 간암의 세계 부담 증가입니다. 환자 수가 증가함에 따라 치료와 완화 치료 사이의 치료 간극을 메우는 TACE와 같은 중간 치료법에 대한 수요도 증가하고 있습니다. 기술적 측면에서는 차세대 색전제, 개선된 카테터 내비게이션 도구, AI를 활용한 영상 분석의 개발로 시술의 효과와 안전성이 향상되고 있습니다. 의료진들은 전신 화학요법이나 수술에 비해 침습성이 낮고 회복 시간이 짧으며 합병증 발생률이 낮은 TACE를 받아들이고 있습니다. 또한, 외래에서 중재적 종양학 치료에 대한 선호도가 높아짐에 따라 병원과 전문 클리닉 환경에서 TACE에 대한 수요가 증가하고 있습니다. 특히 선진국과 경제가 빠르게 발전하고 있는 국가에서는 보험 상환이 합리화되고, TACE가 1차 선택 치료로 적용되면서 환자 접근성이 증가하고 있습니다. 장비 제조업체, 제약사 및 중재적 방사선학 네트워크 간의 전략적 제휴도 기술 혁신과 시장 침투를 촉진하고 있습니다. 이러한 요인들로 인해 TACE는 전 세계적으로 간암의 다학제적 치료에서 중요한 역할을 하고 있습니다.

부문

제품 유형(화학요법제, 방사선 치료제, 약제 용출 입자), 적응증(절제 불능 간세포암, 조기 간세포암), 최종사용자(병원, 진료소, 암 연구센터, 기타 최종사용자)

조사 대상 기업 예(총 42개사)

  • Advaxis Inc.
  • Bayer AG
  • Bellicum Pharmaceuticals
  • Boston Scientific Corporation
  • CELGENE Corporation
  • Cook Medical
  • F. Hoffmann-La Roche Ltd
  • Hikma Pharmaceuticals PLC
  • Isofol Medical AB
  • Kaneka Corporation
  • Medtronic plc
  • Merck & Co., Inc.
  • Merit Medical Systems, Inc.
  • Nippon Kayaku Co., Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Siemens Healthineers AG
  • Sirtex Medical Limited
  • Spectrum Pharmaceuticals, Inc.
  • Terumo Corporation

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 수익원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사했습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월: 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월: 최종 관세 재설정

고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역과 관세의 영향 분석 :

미국 <>& 중국 <>& 멕시코 <>& 캐나다 <>&EU <>& 일본 <>& 인도 <>& 기타 176개국

업계 최고의 이코노미스트: Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트 그룹을 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.06.19

Global Transarterial Chemoembolization Market to Reach US$21.8 Billion by 2030

The global market for Transarterial Chemoembolization estimated at US$16.8 Billion in the year 2024, is expected to reach US$21.8 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Chemotherapeutic Agents, one of the segments analyzed in the report, is expected to record a 4.3% CAGR and reach US$11.5 Billion by the end of the analysis period. Growth in the Radio Therapeutic Agents segment is estimated at 5.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.6 Billion While China is Forecast to Grow at 8.1% CAGR

The Transarterial Chemoembolization market in the U.S. is estimated at US$4.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.5 Billion by the year 2030 trailing a CAGR of 8.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.9% and 3.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR.

Global "Transarterial Chemoembolization" Market - Key Trends & Drivers Summarized

Why Is Transarterial Chemoembolization Becoming a Standard for Liver Cancer Treatment Worldwide?

Transarterial chemoembolization (TACE) has emerged as a preferred and increasingly standardized therapy for intermediate-stage hepatocellular carcinoma (HCC), the most common form of primary liver cancer. Unlike systemic chemotherapy, TACE delivers high-dose chemotherapy directly into the hepatic artery feeding the tumor while simultaneously blocking the blood supply, leading to targeted drug exposure and localized tumor necrosis. This dual mechanism has proven particularly effective in patients ineligible for surgical resection or liver transplantation. TACE is also being adopted as a bridging therapy for patients awaiting transplantation, helping to stabilize disease progression. Globally, the incidence of liver cancer is rising due to factors such as chronic hepatitis B and C infections, non-alcoholic fatty liver disease (NAFLD), and alcohol-related liver damage. These trends have increased demand for locoregional therapies like TACE, which offer improved survival rates and disease control with a lower systemic toxicity profile. Emerging guidelines by international oncology societies are endorsing TACE as a frontline or combination treatment for liver malignancies, thereby reinforcing its central role in therapeutic pathways and boosting adoption among healthcare providers worldwide.

How Are Drug Delivery Innovations and Imaging Technologies Enhancing TACE Outcomes?

The effectiveness of TACE has significantly improved through advancements in embolic materials, catheter technology, and imaging guidance systems. Drug-eluting beads (DEBs), which allow for controlled and sustained release of chemotherapy agents at the tumor site, have largely replaced traditional lipiodol-based formulations in many markets, reducing systemic exposure and improving response rates. Technological enhancements in microcatheters and steerable delivery systems have made it possible to navigate complex vascular anatomies with precision, minimizing damage to healthy liver tissue. At the same time, real-time imaging modalities such as cone-beam CT and 3D angiography have revolutionized intra-procedural visualization, allowing for highly targeted delivery and immediate verification of treatment success. These innovations have also paved the way for personalized treatment plans, where tumor size, location, and vascularity are factored into decisions on embolic type, particle size, and dosing schedules. Additionally, the integration of AI in imaging analytics is beginning to assist interventional radiologists in pre-procedural planning and post-procedural outcome assessments, improving consistency and long-term prognoses. These technology-led improvements are not only boosting clinical outcomes but also expanding the candidate pool for TACE.

Is the Global Healthcare Landscape Ready for the Widespread Adoption of TACE?

The global healthcare ecosystem is increasingly receptive to the widespread adoption of transarterial chemoembolization, supported by expanding interventional radiology infrastructure and a growing base of trained specialists. In high-income countries, the presence of sophisticated imaging suites, multidisciplinary tumor boards, and dedicated oncology pathways has allowed for the seamless integration of TACE into liver cancer care algorithms. Meanwhile, middle-income countries are investing heavily in minimally invasive cancer care, recognizing TACE’s value in resource-constrained settings where access to advanced surgery or systemic therapies is limited. In Asia-Pacific, where liver cancer incidence is particularly high, governments are including TACE in public insurance schemes and national cancer control programs, fueling rapid market expansion. Private sector investments in ambulatory surgical centers and oncology-focused hospitals are also contributing to the increased availability of TACE in urban and peri-urban regions. However, challenges remain in low-income countries due to inadequate imaging capabilities and a shortage of skilled interventional radiologists. Efforts by global health organizations to improve access through mobile IR units, training programs, and public-private partnerships are beginning to address these disparities, gradually democratizing access to this life-extending procedure.

The Growth in the Transarterial Chemoembolization Market Is Driven by Several Factors…

The growth in the transarterial chemoembolization market is driven by several factors rooted in disease prevalence, medical innovation, and healthcare system evolution. A primary driver is the rising global burden of liver cancer, fueled by aging populations, viral hepatitis, alcohol consumption, and metabolic disorders. As patient volumes increase, so does the need for intermediate therapies like TACE that fill the treatment gap between curative and palliative care. From a technological perspective, the development of next-generation embolic agents, improved catheter navigation tools, and AI-powered imaging analytics is enhancing procedural efficacy and safety. Healthcare providers are embracing TACE for its minimally invasive profile, shorter recovery times, and lower complication rates compared to systemic chemotherapy or surgery. Additionally, the growing preference for outpatient interventional oncology treatments is expanding demand for TACE in both hospital and specialty clinic settings. Insurance reimbursements, particularly in developed and rapidly developing economies, are being streamlined to cover TACE as a first-line therapy, increasing patient access. Strategic collaborations between device manufacturers, pharma companies, and interventional radiology networks are also fostering innovation and market penetration. Collectively, these factors are positioning TACE as a vital pillar in the multidisciplinary management of liver cancer worldwide.

SCOPE OF STUDY:

The report analyzes the Transarterial Chemoembolization market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Chemotherapeutic Agents, Radio Therapeutic Agents, Drug-Eluting Particles); Indication (Unresectable HCC, Early-Stage HCC); End-Use (Hospitals, Clinics, Cancer Research Centers, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Advaxis Inc.
  • Bayer AG
  • Bellicum Pharmaceuticals
  • Boston Scientific Corporation
  • CELGENE Corporation
  • Cook Medical
  • F. Hoffmann-La Roche Ltd
  • Hikma Pharmaceuticals PLC
  • Isofol Medical AB
  • Kaneka Corporation
  • Medtronic plc
  • Merck & Co., Inc.
  • Merit Medical Systems, Inc.
  • Nippon Kayaku Co., Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Siemens Healthineers AG
  • Sirtex Medical Limited
  • Spectrum Pharmaceuticals, Inc.
  • Terumo Corporation

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Transarterial Chemoembolization - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Liver Cancer and Hepatocellular Carcinoma Propels Demand for TACE Procedures
    • Increasing Preference for Minimally Invasive Oncology Treatments Expands TACE Adoption
    • Advancements in Drug-Eluting Beads Technology Strengthen Clinical Outcomes and Market Appeal
    • Expanding Use of TACE in Palliative Cancer Care Throws the Spotlight on Targeted Therapies
    • Growing Acceptance of TACE as a First-Line Treatment Drives Procedural Volumes Globally
    • Integration of Imaging Guidance Systems Enhances Precision and Spurs Market Innovation
    • Favorable Reimbursement Scenarios in Developed Markets Support Wider Procedural Uptake
    • Aging Population and Comorbidities Increase Patient Pool for Non-Surgical Therapies
    • Expansion of Interventional Radiology Infrastructure in Emerging Markets Sustains Global Growth
    • Improved Catheterization Techniques Propel Success Rates and Professional Confidence in TACE
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Transarterial Chemoembolization Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Transarterial Chemoembolization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Transarterial Chemoembolization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Chemotherapeutic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Chemotherapeutic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Chemotherapeutic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Radio Therapeutic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Radio Therapeutic Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Radio Therapeutic Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Drug-Eluting Particles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Drug-Eluting Particles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Drug-Eluting Particles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Unresectable HCC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Unresectable HCC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Unresectable HCC by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Early-Stage HCC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Early-Stage HCC by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Early-Stage HCC by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Cancer Research Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Cancer Research Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Cancer Research Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Transarterial Chemoembolization by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Transarterial Chemoembolization by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Transarterial Chemoembolization by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Transarterial Chemoembolization by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 164: India Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 167: India Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Transarterial Chemoembolization by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Transarterial Chemoembolization by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Transarterial Chemoembolization by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Transarterial Chemoembolization by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Transarterial Chemoembolization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Transarterial Chemoembolization by Product Type - Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Transarterial Chemoembolization by Product Type - Percentage Breakdown of Value Sales for Chemotherapeutic Agents, Radio Therapeutic Agents and Drug-Eluting Particles for the Years 2015, 2025 & 2030
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Transarterial Chemoembolization by Indication - Unresectable HCC and Early-Stage HCC Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Transarterial Chemoembolization by Indication - Percentage Breakdown of Value Sales for Unresectable HCC and Early-Stage HCC for the Years 2015, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Transarterial Chemoembolization by End-Use - Hospitals, Clinics, Cancer Research Centers and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Transarterial Chemoembolization by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics, Cancer Research Centers and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제